Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis

Kulu, Ugur; Tiftikcioglu, Bedile; Zorlu, Yasar; Cetiner, Mustafa; Sener, Ufuk; Tuna, GAMZE; Kirkali, Guldal

doi:10.5152/npa.2016.12382

Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis

Kulu U., Tiftikcioglu B. I., Zorlu Y., Cetiner M., Sener U., Tuna G., ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.54, sa.1, ss.57-61, 2017 (SCI-Expanded, Scopus, TRDizin)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 54 Sayı: 1
Basım Tarihi: 2017
Doi Numarası: 10.5152/npa.2016.12382
Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.57-61
Anahtar Kelimeler: Interleukin-10, intravenous methylprednisolone, glucocorticoids, relapsing-remitting multiple sclerosis, treatment duration
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Introduction: Relapses of multiple sclerosis (MS) are usually treated with high-dose intravenous methylprednisolone (IVMP), given over 3-10 days. There is no consensus on the optimal duration of treatment. In this study, we aimed to investigate whether longer treatment provides additional short-term clinical benefits assessed by the change in plasma cytokine levels and EDSS scores in patients with relapsing-remitting MS (RRMS).